Ask AI
VICEROY
VICEROY: Venetoclax + Azacitidine + Gilteritinib in Patients With ND FLT3-Mutated AML Ineligible for Intensive Induction Chemotherapy

Released: December 12, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: December 12, 2025